Dr. Agarwal on Frontline Treatment in Kidney Cancer

Neeraj Agarwal, MD
Published: Tuesday, Jul 17, 2018



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses his preferred frontline treatment for patients with kidney cancer.

In a randomized phase III trial, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was superior to sunitinib (Sutent) in intermediate- and poor-risk patients with newly diagnosed metastatic renal cell carcinoma (RCC). There is stronger evidence favoring the combination in these patients, says Agarwal.

However, thorough evaluation of the data showed that favorable-risk patients experienced greater benefit with sunitinib. For those patients, Agarwal says that a VEGF tyrosine kinase inhibitor is the drug of choice. Since cabozantinib (Cabometyx) bested sunitinib in a randomized phase II trial, Agarwal recommends cabozantinib for this subgroup.

Most of the patients who had 1% or greater PD-L1 expression in the phase III trial derived the most benefit from the combination of nivolumab and ipilimumab. However, the majority of patients’ tumors in that trial did not have high PD-L1 expression. Therefore, in select patients whose tumors do not express PD-L1, Agarwal tends to favor cabozantinib.
SELECTED
LANGUAGE


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses his preferred frontline treatment for patients with kidney cancer.

In a randomized phase III trial, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was superior to sunitinib (Sutent) in intermediate- and poor-risk patients with newly diagnosed metastatic renal cell carcinoma (RCC). There is stronger evidence favoring the combination in these patients, says Agarwal.

However, thorough evaluation of the data showed that favorable-risk patients experienced greater benefit with sunitinib. For those patients, Agarwal says that a VEGF tyrosine kinase inhibitor is the drug of choice. Since cabozantinib (Cabometyx) bested sunitinib in a randomized phase II trial, Agarwal recommends cabozantinib for this subgroup.

Most of the patients who had 1% or greater PD-L1 expression in the phase III trial derived the most benefit from the combination of nivolumab and ipilimumab. However, the majority of patients’ tumors in that trial did not have high PD-L1 expression. Therefore, in select patients whose tumors do not express PD-L1, Agarwal tends to favor cabozantinib.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x